Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

126
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
126
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

121
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
121
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

115
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
115
Allergic Drug Reactions01:27

Allergic Drug Reactions

1.6K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.6K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

2.7K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Global advances and future directions in lung cancer care: expert consensus and strategic priorities.

ESMO open·2026
Same author

Corrigendum to "Plasmodium yoelii: Contribution of oocysts melanization to natural refractoriness in Anopheles dirus" [Exp. Parasitol. 116 (2007) 433-439].

Experimental parasitology·2024
Same author

Recognition and expressed insight on Advanced Directives by patients with cancer.

Irish medical journal·2024
Same author

Clinical features and outcomes of advanced HER2+ esophageal/GEJ cancer with brain metastasis.

ESMO open·2023
Same author

A brave NEO world: Neoadjuvant osimertinib in resectable EGFR-mutant NSCLC.

Lung cancer (Amsterdam, Netherlands)·2023
Same journal

The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient.

Clinical pharmacology and therapeutics·2026
Same journal

Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers.

Clinical pharmacology and therapeutics·2026
Same journal

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

Clinical pharmacology and therapeutics·2026
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026
Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026
See all related articles

Related Experiment Video

Updated: Mar 21, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.2K

Immune-Related Adverse Events From Immune Checkpoint Inhibitors.

K A Marrone1, W Ying2, J Naidoo1

  • 1Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.

Clinical Pharmacology and Therapeutics
|May 13, 2016
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitors targeting CTLA-4, PD-1, and PD-L1 are revolutionizing cancer treatment. Understanding and managing their immune-related adverse events (irAEs) is crucial for patient care.

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.9K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Related Experiment Videos

Last Updated: Mar 21, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.2K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.9K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Immune checkpoint inhibitors (ICIs) targeting CTLA-4, PD-1, and PD-L1 have emerged as a cornerstone of modern cancer therapy.
  • Despite their efficacy, ICIs can elicit immune-related adverse events (irAEs) due to their mechanism of action.
  • Effective management of irAEs is critical for optimizing patient outcomes and treatment tolerance.

Purpose of the Study:

  • To provide a comprehensive overview of the current understanding of irAEs associated with ICI therapy.
  • To detail the incidence, clinical manifestations, underlying mechanisms, and management strategies for key irAEs.
  • To highlight areas where further research is needed to improve irAE prediction and treatment.

Main Methods:

  • Systematic review of published literature on ICI-related irAEs.
  • Analysis of clinical trial data and real-world evidence regarding irAEs.
  • Synthesis of current knowledge on the pathophysiology and clinical features of irAEs.

Main Results:

  • ICIs, including those targeting CTLA-4, PD-1, and PD-L1, are associated with a spectrum of irAEs.
  • The frequency and severity of irAEs vary depending on the specific agent, combination therapy, and patient factors.
  • Key irAEs discussed include dermatitis, colitis, hepatitis, endocrinopathies, and pneumonitis.

Conclusions:

  • ICI therapy has significantly advanced cancer treatment, but requires careful monitoring for irAEs.
  • A thorough understanding of irAE mechanisms and clinical presentations is essential for timely diagnosis and effective management.
  • Continued research into irAEs will further refine treatment strategies and improve patient safety in immuno-oncology.